Please login to the form below

Not currently logged in
Email:
Password:

Ex-BMS exec jumps to Gilead to lead research group

Gilead appoints Michael Quigley to lead research team

A former Bristol-Myers Squibb executive has jumped ship to Gilead, where he will head up the company’s research biology group.

Michael QuigleyMichael Quigley (pictured left) joins Gilead from BMS, where he most recently served as vice president and head of the company’s Tumour Microenvironment Modulation Thematic Research Center and site head of the Redwood City, California location.

At BMS, Quigley held responsibility for setting the strategy for the company’s oncology discovery portfolio and business development activities. He also oversaw target identification, validation and preclinical development of large and small molecule therapies.

Gilead has also simultaneously announced the promotion of Linda Higgins, who has recently taken on the role of senior vice president and head of external innovation.

Linda HigginsHiggins (pictured right) joined Gilead in 2010 to lead an expansion of the company’s biology organisation. That included the expansion of the company’s biologics and biomarker functions, as well as the addition of inflammation, oncology and immunology discovery groups.

Under her leadership, Gilead’s biology organisation supported the discovery and development of eight marketed products and the development of more than 30 compounds into development.

“We are very pleased to welcome Mike to Gilead and Linda to her new role, as we seek to build and scale our access to scientific innovation, both internally and externally,” commented William Lee. “These appointments strengthen our research discovery organisation and will help position us to reach our ambitious goal of bringing 10 new transformative therapies to patients over the next 10 years.”

Article by
Lucy Parsons

21st February 2020

From: Research

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
Serious about sustainability?
Get to know our new Sustainability Officer here at Cuttsy+Cuttsy...